Suchen
CorMedix Inc
CRMDZur Watchlist hinzufügen
8.750USD
+0.280+3.31%
Handelsschluss 07/02, 13:00（ET）Kurse um 15 Minuten verzögert
686.45MMarktkapitalisierung
3.60KGV TTM
mehr Informationen über CorMedix Inc Unternehmen
CorMedix Inc. is a biopharmaceutical company. The Company is focused on developing and commercializing therapeutic products for the prevention and treatment of life-threatening conditions and diseases. The Company is focused on commercializing its lead product, DefenCath, which is an antimicrobial catheter lock solution approved to reduce the incidence of catheter-related bloodstream infections in adult patients with kidney failure receiving chronic hemodialysis through a central venous catheter. DefenCath is a formulation of taurolidine 13.5 milligrams per milliliter (mg/mL), and heparin 1000 USP Units/mL indicated to reduce the incidence of catheter-related bloodstream infections (CRBSI) in adult patients with kidney failure receiving chronic hemodialysis through a central venous catheter (CVC). The Company is also commercializing a portfolio of anti-infective products including MINOCIN, REZZAYO, VABOMERE, ORBACTIV, BAXDELA, and KIMYRSA, as well as TOPROL-XL.
CorMedix Inc Informationen
BörsenkürzelCRMD
Name des UnternehmensCorMedix Inc
IPO-datumMar 25, 2010
CEOTodisco (Joseph)
Anzahl der mitarbeiter64
WertpapierartOrdinary Share
GeschäftsjahresendeMar 25
Addresse300 Connell Drive
StadtBERKELEY HEIGHTS
BörseNASDAQ OMX - NASDAQ BASIC
LandUnited States of America
Postleitzahl07922
Telefon19085179500
Websitehttps://cormedix.com/
BörsenkürzelCRMD
IPO-datumMar 25, 2010
CEOTodisco (Joseph)
Führungskräfte von CorMedix Inc
Name
Name/Position
Position
Aktienbesitz
Veränderung
Mr. Joseph (Joe) Todisco
Mr. Joseph (Joe) Todisco
Chief Executive Officer, Director
Chief Executive Officer, Director
401.08K
-41.48%
Ms. Susan Blum
Ms. Susan Blum
Chief Financial Officer
Chief Financial Officer
132.74K
+47.50%
Mr. Steven W. Lefkowitz
Mr. Steven W. Lefkowitz
Independent Director
Independent Director
127.65K
-4.27%
Ms. Janet M. Dillione
Ms. Janet M. Dillione
Independent Director
Independent Director
38.47K
-14.17%
Mr. Gregory Scott (Greg) Duncan
Mr. Gregory Scott (Greg) Duncan
Independent Director
Independent Director
38.33K
-14.23%
Mr. Robert Stewart
Mr. Robert Stewart
Independent Director
Independent Director
36.00K
-15.15%
Mr. Myron M. Kaplan, J.D.
Mr. Myron M. Kaplan, J.D.
Independent Chairman of the Board
Independent Chairman of the Board
--
--
Dr. Alan William Dunton, M.D.
Dr. Alan William Dunton, M.D.
Independent Director
Independent Director
--
--
Ms. Elizabeth (Liz) Massonhurlburt
Ms. Elizabeth (Liz) Massonhurlburt
Chief Operating Officer
Chief Operating Officer
--
--
Dr. Matthew T. (Matt) David, M.D.
Dr. Matthew T. (Matt) David, M.D.
Chief Business Officer
Chief Business Officer
--
--
Mehr Anzeigen
Name
Name/Position
Position
Aktienbesitz
Veränderung
Mr. Joseph (Joe) Todisco
Mr. Joseph (Joe) Todisco
Chief Executive Officer, Director
Chief Executive Officer, Director
401.08K
-41.48%
Ms. Susan Blum
Ms. Susan Blum
Chief Financial Officer
Chief Financial Officer
132.74K
+47.50%
Mr. Steven W. Lefkowitz
Mr. Steven W. Lefkowitz
Independent Director
Independent Director
127.65K
-4.27%
Ms. Janet M. Dillione
Ms. Janet M. Dillione
Independent Director
Independent Director
38.47K
-14.17%
Mr. Gregory Scott (Greg) Duncan
Mr. Gregory Scott (Greg) Duncan
Independent Director
Independent Director
38.33K
-14.23%
Mr. Robert Stewart
Mr. Robert Stewart
Independent Director
Independent Director
36.00K
-15.15%
Häufig gestellte Fragen
Wer sind die fünf größten Anteilseigner von CorMedix Inc?
Die fünf größten Anteilseigner von CorMedix Inc sind: Mr. Joseph (Joe) Todisco
Wie viele Institutionen halten Anteile an CorMedix Inc (CRMD)?
Mit Stand vom 2026Q1 halten 390 Institutionen Anteile an CorMedix Inc, mit einem Gesamtmarktwert von etwa 43.28M, was 55.17% der Gesamtanteile entspricht. Im Vergleich zum 2025Q4 ist der institutionelle Aktienbesitz um -18630389.00 gestiegen.